Phase 2 Breast Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have cancer that can be measured on a CT scan and/or MRI, or measured with calipers if the tumour is on or just under the skin
• People with triple-negative breast cancer (TNBC) that has spread or come back, either locally or to other parts of the body
• People with hormone receptor-positive, HER2-negative breast cancer (HR+/HER2-) that has spread or come back, either locally or to other parts of the body
• People who have cancer that has spread to the brain, provided it has already been treated, they have had no symptoms for at least 14 days, they are not currently receiving any treatment for the brain cancer (such as surgery, radiation, or higher-dose steroids), and there is no cancer affecting the spinal fluid or causing spinal cord compression

Who may not be able to join:

• People with a history of most autoimmune diseases — though some conditions may still be acceptable, including vitiligo, psoriasis, eczema or other skin autoimmune conditions not needing systemic treatment, well-controlled thyroid conditions (such as Graves' disease that has been stable for more than 4 weeks, or hypothyroidism managed with thyroid replacement), hair loss (alopecia), arthritis managed only with over-the-counter anti-inflammatory tablets, and well-controlled adrenal insufficiency on replacement therapy (confirm with trial site)
• People who have had major surgery or a serious injury within 8 weeks before the first treatment in the study
• People whose surgical or injury wounds have not fully healed
• People with significant heart or blood vessel disease, stomach or bowel problems, active inflammatory conditions, or serious lung problems (confirm with trial site for specific definitions)
• People who have an active serious infection (viral, bacterial, or fungal) that required treatment given through a drip or injection within 7 days before starting the study treatment
• People who have received a live virus vaccine within 4 weeks before starting the study treatment — standard inactivated flu vaccines are allowed
• People who are HIV positive, or hepatitis B or C positive, with disease that is not well controlled
• People who have had a second cancer that has not been in remission for at least 1 year — some exceptions may apply, such as certain skin cancers, early-stage cervical changes, low-risk localised prostate cancer, or some slow-growing cancers that have never needed systemic treatment (confirm with trial site)
• People who are pregnant, likely to become pregnant, or who are breastfeeding
• People who have taken more than 10 mg per day of prednisone (or an equivalent steroid) or other immune-suppressing medications within 7 days before starting the study treatment — topical, eye drop, inhaled, or nasal steroid preparations are generally allowed

Important: Always verify eligibility with the trial site directly before applying.